Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma.

Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Br J Cancer. 2013 Jan 15;108(1):131-8. doi: 10.1038/bjc.2012.537.

2.

GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.

Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30.

3.

Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.

Eggers H, Steffens S, Grosshennig A, Becker JU, Hennenlotter J, Stenzl A, Merseburger AS, Kuczyk MA, Serth J.

Int J Oncol. 2012 May;40(5):1650-8. doi: 10.3892/ijo.2012.1367. Epub 2012 Feb 10.

PMID:
22327210
4.

Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.

Dubrowinskaja N, Gebauer K, Peters I, Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS, Stenzl A, Grünwald V, Kuczyk MA, Serth J.

Cancer Med. 2014 Apr;3(2):300-9. doi: 10.1002/cam4.181. Epub 2014 Jan 27.

5.

GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.

Peters I, Gebauer K, Dubrowinskaja N, Atschekzei F, Kramer MW, Hennenlotter J, Tezval H, Abbas M, Scherer R, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Oncol Rep. 2014 Apr;31(4):1523-30. doi: 10.3892/or.2014.3030. Epub 2014 Feb 18.

6.

SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.

Atschekzei F, Hennenlotter J, Jänisch S, Großhennig A, Tränkenschuh W, Waalkes S, Peters I, Dörk T, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Epigenetics. 2012 May;7(5):447-57. doi: 10.4161/epi.19614. Epub 2012 May 1.

PMID:
22419128
7.

The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.

Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlbäck B.

Eur J Cancer. 2014 Jul;50(10):1758-65. doi: 10.1016/j.ejca.2014.03.281. Epub 2014 Apr 30.

PMID:
24793999
8.

Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma.

Peters I, Dubrowinskaja N, Kogosov M, Abbas M, Hennenlotter J, von Klot C, Merseburger AS, Stenzl A, Scherer R, Kuczyk MA, Serth J.

BMC Cancer. 2014 Feb 17;14:101. doi: 10.1186/1471-2407-14-101.

9.

Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.

Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.

10.

[Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression].

Beresneva EV, Rykov SV, Hodyrev DS, Pronina IV, Ermilova VD, Kazubskaia TP, Braga EA, Loginov VI.

Genetika. 2013 Mar;49(3):366-75. Russian.

PMID:
23755536
11.

DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).

Evelönn EA, Degerman S, Köhn L, Landfors M, Ljungberg B, Roos G.

Tumour Biol. 2016 Aug;37(8):10219-28. doi: 10.1007/s13277-016-4893-5. Epub 2016 Jan 30.

PMID:
26831665
12.

Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma.

Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X.

Oncogene. 2010 Oct 21;29(42):5724-8. doi: 10.1038/onc.2010.305. Epub 2010 Aug 2.

PMID:
20676129
13.

Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma.

Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L.

Int Urol Nephrol. 2013 Apr;45(2):373-9. doi: 10.1007/s11255-012-0374-y. Epub 2013 Feb 3.

PMID:
23378187
14.

DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.

Fisel P, Kruck S, Winter S, Bedke J, Hennenlotter J, Nies AT, Scharpf M, Fend F, Stenzl A, Schwab M, Schaeffeler E.

Clin Cancer Res. 2013 Sep 15;19(18):5170-81. doi: 10.1158/1078-0432.CCR-13-1180. Epub 2013 Jul 23.

15.

Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma.

Nakata W, Uemura M, Sato M, Fujita K, Jingushi K, Ueda Y, Kitae K, Tsujikawa K, Nonomura N.

Oncotarget. 2015 Aug 28;6(25):21645-54.

16.

Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.

van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, van Poppel H, Lerut E, Schuebel KE, Ahuja N, Herman JG, de Bruïne AP, van Engeland M.

Am J Pathol. 2010 Feb;176(2):575-84. doi: 10.2353/ajpath.2010.090442. Epub 2009 Dec 30.

17.

Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.

Lin YL, Wang YL, Fu XL, Ma JG.

Med Sci Monit. 2014 Nov 22;20:2380-5. doi: 10.12659/MSM.892433.

18.

Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker.

de Martino M, Klatte T, Haitel A, Marberger M.

Cancer. 2012 Jan 1;118(1):82-90. doi: 10.1002/cncr.26254. Epub 2011 Jun 28.

19.

Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma.

Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, Junker K.

World J Urol. 2011 Jun;29(3):367-73. doi: 10.1007/s00345-010-0633-4. Epub 2011 Jan 13.

PMID:
21229250
20.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project.; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation..

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.

Supplemental Content

Support Center